Videos

President and Chief Operating Officer, Julien Pham, MD, MPH, delivers a presentation about the company’s unique, leading-edge gene therapies and participated in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV.

Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex™ which, in combination with erlotinib, is in Phase II testing against NSCLC.

Julien Pham, MD, MPH and COO of Genprex, Inc. details our lead product candidate, Oncoprex™ (currently in development and not FDA approved). It uses a revolutionary approach to cancer treatment that combines the features of Gene Therapy, Immunotherapy, and Nanotechnology to harness the body’s own mechanisms to fight cancer.